

DROPSCREEN™ NEW ALLERGY SCREENING KIT AND REAGENT APPROVED
— FASTER TEST RESULTS WITH NEW KIT–REAGENT COMBINATION —

Nippon Chemiphar Co., Ltd.
(TSE: 4539)
August 17, 2026

Nippon Chemiphar Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President and CEO: Kazushiro Yamaguchi) announces that the manufacturing and marketing notification has been completed for “DropScreen A-2” a measuring device (Marketing Authorization Holder: Ueda Japan Radio Co., Ltd.) and manufacturing and marketing certification has been obtained for its new reagent “DropScreen Inhalant Allergens KR-1” (Marketing Authorization Holder: Nippon Chemiphar Co., Ltd.), which can be used with the new screening kit. We will now proceed with preparations for the launch of these new screening kit and reagent.

Launched in February 2020, the DropScreen A-1 and DropScreen specific IgE screening kit ST-1 can measure 41 allergens from a single drop (20 µL) of blood in 30 minutes, providing a new option for allergy testing that can be performed within medical institutions, where outsourcing to testing laboratories had previously been the predominant practice.

Because the tests can be performed using a small blood sample collected from a fingertip, they can help reduce patients’ reluctance to have blood drawn using a syringe as well as the burden on healthcare professionals. As a result, adoption has been steadily increasing, particularly at clinics, and more than 1,800 DropScreen A-1 units had been installed at medical institutions in Japan as of the end of March 2026.

The combination of the new DropScreen A-2 screening kit and new reagent DropScreen inhalant allergens KR-1, will make it possible to measure 20 items, including total IgE, in 15 minutes, enabling the provision of test results to patients even more quickly. We will continue to contribute to the achievement of rapid and appropriate allergy screening in clinical settings through the DropScreen series.

For further information contact:

Corporate Planning Department, Nippon Chemiphar Co., Ltd.

E-mail: ir@chemiphar.co.jp